SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Hyperliquid Strategies, Inc. is a holding and operating company, which engages in the business of crypto asset management. The firm operates as a digital asset treasury company which focuses on the Hyperliquid ecosystem. The company was founded on July 2, 2025 and is headquartered in New York, NY.

Hyperliquid Strategies Inc.

Hyperliquid Strategies is gaining significant attention as investors speculate on its position as a digital asset infrastructure play, with the community actively tracking its correlation to the HYPE token and the broader rise in perpetual futures trading. Discussions are dominated by potential institutional interest and the stock's role as a crypto-equity hybrid, despite ongoing debates regarding dilution and its historical performance.

Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Miami, FL.

Summit Therapeutics Inc

Summit Therapeutics is trending as investors focus on the company's oncology pipeline following major data updates from the HARMONi-6 trial and its upcoming PDUFA date. The community is actively debating the potential for ivonescimab to challenge existing standards of care, with sentiment split between bullish enthusiasm over clinical results and concerns regarding trial design and regulatory pathways.

Zoracles

Zoracles is drawing significant attention as investors speculate on potential price rebounds, with many viewing current pullbacks as strategic accumulation opportunities. The community remains focused on the token's integration with the Base ecosystem and its potential utility as a creator-focused asset, despite broader market volatility and mixed sentiment regarding its short-term price action.

Gitlawb is a decentralized code collaboration platform designed for AI agents and human developers. It provides a Git-compatible hosting layer where repositories are stored across IPFS, Filecoin, and Arweave, and peer connectivity is handled through libp2p rather than a central server.  Identity on Gitlawb is based on decentralized identifiers (DIDs) using Ed25519 keys. Access control and delegation between users and agents are expressed as UCAN (User Controlled Authorization Networks) capabilities, allowing scoped, revocable permissions to be granted without a central authority. Each identity carries an on-chain trust score derived from verified contributions.  The protocol is accessed through three main surfaces: a Rust node (gitlawb-node) that serves repositories over HTTP and libp2p, a command-line client (gl) that handles identity, repositories, issues, bounties, and UCAN delegation, and a git remote helper (git-remote-gitlawb) that allows standard Git clients to push and pull using gitlawb:// URLs.  Additional products in the ecosystem include MiroClaw, an on-chain prediction market; Gitlawb Spawn, an AI agent orchestration tool; OpenClaude, an open-source agent harness aligned with Playground and Spawn; and a developer playground for testing agent interactions against the protocol.

Gitlawb

Gitlawb is trending as investors highlight its vision as a decentralized, AI-native alternative to GitHub, specifically designed for autonomous agents to manage repositories and coordinate tasks on-chain. The community is actively discussing the project's aggressive supply reduction plans, potential exchange listings, and strategic partnerships, with many focusing on its long-term utility in the evolving AI infrastructure stack.

Avalanche is a high throughput smart contract blockchain&nbsp;platform. Validators secure the network through a proof-of-stake consensus protocol. It is said to be fast, low cost, and environmental friendly.

Avalanche

Avalanche is facing intense selling pressure as it hits multi-year lows, triggering widespread frustration among community members who are debating whether to hold through the volatility or capitulate at a loss. Sentiment is heavily polarized between long-term investors emphasizing fundamental RWA adoption and institutional integration, and traders highlighting the lack of short-term price momentum.

Chronobank

Chronobank is currently generating significant community buzz due to a recent security incident involving the unauthorized minting of tokens, prompting the company to initiate buybacks and burns to stabilize supply. Investors are closely monitoring the asset's low circulating supply and potential for volatility, with many debating whether it functions as a long-term utility play or a speculative pump-and-dump opportunity.

BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

BioNTech SE - ADR

BioNTech is trending due to the company's recent strategic pivot away from COVID-19 revenue toward a diversified oncology pipeline, which includes multiple late-stage clinical trials. Community sentiment is mixed, with some investors optimistic about the potential of their bispecific antibody and ADC programs to disrupt the standard of care, while others remain skeptical about the leadership transition and the long-term viability of mRNA technology.

TKO Group Holdings, Inc. engages in the provision of sports and entertainment. It operates through the following segments: Ultimate Fighting Championship (UFC), World Wrestling Entertainment (WWE), and IMG. The UFC segment refers to a global sports brand and media content company. The WWE segment is involved in media organizations and global leaders in sports entertainment. The IMG segment manages the operations of the IMG business and on location. The company was founded on March 29, 2023 and is headquartered in New York, NY.

TKO Group Holdings Inc - Ordinary Shares - Class A

TKO GROUP HLDGS INC

TKO Group Holdings is trending as investors weigh significant growth catalystsincluding S&P 500 inclusion, a massive share buyback program, and the expansion of the companys streaming reachagainst vocal community frustration over ticket pricing, content fatigue, and controversial management decisions. While bulls highlight robust earnings and a clear long-term trajectory anchored by UFC and WWE, bears remain focused on potential accounting concerns and broader market volatility impacting the stock's recent momentum.

Li Auto, Inc. engages in the design, development, manufacture, and sale of premium smart electric vehicles. Its products include Li MEGA, a high-tech flagship family MPV, Li L9, a six-seat flagship family SUV, and Li L8, a six-seat premium family SUV, and Li L7, a five-seat flagship family SUV. The firm also offers in-house development efforts on its proprietary range extension system, next-generation electric vehicle technology, and smart vehicle solutions. The company was founded by Xiang Li in April 2015 and is headquartered in Beijing, China.

Li Auto Inc - ADR

Li Auto Inc is currently under intense scrutiny from the investment community as shareholders brace for quarterly earnings, with concerns centering on margin pressure and slowing delivery momentum. Discussions are dominated by debates over the company's competitive position against rivals like Nio, skepticism regarding its pivot toward battery-electric vehicles, and market reactions to a softer delivery outlook.

Select Sector SPDR Trust (The) - State Street Consumer Staples Select Sector SPDR ETF

Consumer Staples Select Sector SPDR Fund

The Consumer Staples sector is seeing increased attention as investors rotate toward defensive assets amid growing market volatility and inflation concerns. Community discussion is currently centered on these stocks acting as a potential safe haven while participants monitor broader sector rotation patterns.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Edgewise Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference on May 20, 2026

Edgewise Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference on May 20, 2026 Edgewise Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference on...

Joanne Donovan Sells 50,000 Shares of Edgewise Therapeutics (NASDAQ:EWTX) Stock

Edgewise Therapeutics, Inc. (NASDAQ:EWTX - Get Free Report) CMO Joanne Donovan sold 50,000 shares of the firm's stock in a transaction dated Tuesday, May 5th. The stock was sold at an average price of $38.57, for a total transaction of $1,928,500.00. Following the completion of the transaction, the...

Edgewise Therapeutics (NASDAQ:EWTX) CMO Sells $163,646.70 in Stock

Edgewise Therapeutics, Inc. (NASDAQ:EWTX - Get Free Report) CMO Joanne Donovan sold 5,230 shares of the firm's stock in a transaction dated Monday, May 4th. The shares were sold at an average price of $31.29, for a total value of $163,646.70. Following the sale, the chief marketing officer owned...

CYTK Stock Jumped To Over 2-Year Highs On HCM Trial Outcome – So, Why Are Analysts Bullish On Edgewise Therapeutics?

Equity

The company said Aficamten for patients with symptomatic non-obstructive hypertrophic cardiomyopathy met both primary endpoints.

Edgewise Therapeutics (NASDAQ:EWTX) Sets New 52-Week High  - Should You Buy?

Edgewise Therapeutics (NASDAQ:EWTX) Hits New 1-Year High - Time to Buy...

Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules

Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules PR Newswire BOULDER...

Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Given Consensus Rating of "Moderate Buy" by Analysts

Edgewise Therapeutics, Inc. (NASDAQ:EWTX - Get Free Report) has earned an average recommendation of "Moderate Buy" from the nine analysts that are presently covering the company, MarketBeat.com...

Edgewise Therapeutics (EWTX) to Release Earnings on Thursday

Edgewise Therapeutics (NASDAQ:EWTX) will be releasing its Q1 2026 earnings before the market opens on Thursday, May 7. (View Earnings Report at...

Moody Aldrich Partners LLC Has $1.07 Million Holdings in Edgewise Therapeutics, Inc. $EWTX

Moody Aldrich Partners LLC cut its stake in Edgewise Therapeutics, Inc. (NASDAQ:EWTX - Free Report) by 48.0% in the fourth quarter, according to the company in its most recent filing with the...

Edgewise Therapeutics (NASDAQ:EWTX) Sees Large Volume Increase - Here's What Happened

Edgewise Therapeutics (NASDAQ:EWTX) Sees Large Volume Increase - Should You Buy...

Edgewise Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It focuses on the discovery, development and commercialization of innovative treatments for severe, rare muscle disorders for which there is significant unmet medical need. Its platform utilizes custom-built throughput and translatable systems that measure integrated muscle function in whole organ extracts to identify small molecule precision medicines regulating key proteins in muscle tissue, initially focused on addressing rare neuromuscular and cardiac diseases. The company was founded by Badreddin Edris, Alan Russel and Peter A. Thompson in 2017 and is headquartered in Boulder, CO.

EWTX
Edgewise Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Compact View

Latest EWTX News

EWTXEdgewise Therapeutics Inc